{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+powder&page=9", "query": { "intervention": "Control powder", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 697, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+powder&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+powder&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T20:10:51.628Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04226898", "title": "Synbiotic Compound to Reduce Symptoms of Schizophrenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "Synbiotic Supplement", "type": "BIOLOGICAL" }, { "name": "Inert Compound", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sheppard Pratt Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 68, "start_date": "2022-02-21", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 1, "location_summary": "Batlimore, Maryland", "locations": [ { "city": "Batlimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04226898" }, { "nct_id": "NCT02715115", "title": "A Safety Study of NNZ-2566 in Pediatric Rett Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rett Syndrome" ], "interventions": [ { "name": "NNZ-2566", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neuren Pharmaceuticals Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "15 Years", "sex": "FEMALE", "summary": "5 Years to 15 Years · Female only" }, "enrollment_count": 82, "start_date": "2016-03", "completion_date": "2017-01-05", "has_results": false, "last_update_posted_date": "2020-08-14", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Oakland, California • San Diego, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02715115" }, { "nct_id": "NCT04443608", "title": "Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hyperkalemia" ], "interventions": [ { "name": "Patiromer Powder for Oral Suspension [Veltassa]", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Comprehensive Research Associates", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2020-10-08", "completion_date": "2023-06-03", "has_results": false, "last_update_posted_date": "2023-08-31", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 19, "location_summary": "Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04443608" }, { "nct_id": "NCT05996835", "title": "Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Kidney Injury Due to Sepsis" ], "interventions": [ { "name": "TIN816 70 mg lyophilisate powder", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 316, "start_date": "2024-01-18", "completion_date": "2026-05-14", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 19, "location_summary": "Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Johns Creek", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05996835" }, { "nct_id": "NCT00283816", "title": "Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Polycystic Ovary Syndrome" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Oral Contraceptive Pill", "type": "DRUG" }, { "name": "Lifestyle Management Program", "type": "BEHAVIORAL" }, { "name": "Quality of Life Questionnaire", "type": "BEHAVIORAL" }, { "name": "Oral Glucose Tolerance Test", "type": "PROCEDURE" }, { "name": "Blood work", "type": "PROCEDURE" }, { "name": "Abdominal Ultra Sound", "type": "PROCEDURE" }, { "name": "Dual-energy x-ray absorptiometry (DEXA scan)", "type": "PROCEDURE" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "PROCEDURE" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "18 Years", "sex": "FEMALE", "summary": "12 Years to 18 Years · Female only" }, "enrollment_count": 36, "start_date": "2006-01", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2015-05-15", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283816" }, { "nct_id": "NCT03532009", "title": "Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Sodium Zirconium Cyclosilicate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "150 Years", "sex": "ALL", "summary": "18 Years to 150 Years" }, "enrollment_count": 182, "start_date": "2018-06-26", "completion_date": "2020-05-22", "has_results": true, "last_update_posted_date": "2021-06-15", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 14, "location_summary": "National City, California • Stanford, California • Waterbury, Connecticut + 11 more", "locations": [ { "city": "National City", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "New Smyrna Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532009" }, { "nct_id": "NCT06773000", "title": "Nutritional Supplementation in Geriatric Hip Fractures", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Geriatric Hip Fracture" ], "interventions": [ { "name": "XR™ Recovery Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "XR Carbohydrate Loading Supplement", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 118, "start_date": "2025-01-16", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06773000" }, { "nct_id": "NCT00309244", "title": "Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Type 2" ], "interventions": [ { "name": "Technosphere® Insulin Inhalation Powder", "type": "DRUG" }, { "name": "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 677, "start_date": "2006-02", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2014-10-16", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 80, "location_summary": "Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309244" }, { "nct_id": "NCT00283712", "title": "Use of Infliximab for the Treatment of Pemphigus Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pemphigus" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2006-03", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 4, "location_summary": "Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283712" }, { "nct_id": "NCT01113034", "title": "A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma", "Bronchiectasis" ], "interventions": [ { "name": "DAS181 dry powder, formulation F02", "type": "DRUG" }, { "name": "Respitose ML006 (DMV-Fonterra)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ansun Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2010-07", "completion_date": "2011-08-22", "has_results": false, "last_update_posted_date": "2019-03-27", "last_synced_at": "2026-10-29T20:10:51.628Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01113034" } ] }